Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Business Segments — D&A

Similar metrics at other companies

Casey's General Stores logo
CASYReportable Segment — D&A
$115.5M+7.5%
Snap logo
SNAPReportable Segment — D&A
$45.6M+13.9%
PNW
PNWReportable Segment — D&A
-$240M-2.1%
PACS Group logo
PACSReportable Segment — D&A
$18.08M+42.3%
LegalZoom.com, Inc. logo
LZReportable Segment — D&A
$11.27M-0.6%
Consensus Cloud Solutions, Inc. logo
CCSIReportable Segment — D&A
$5.8M+26.8%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.7B-24.8%
Enterprise value$1.22B-33.3%
P/S31×-4.0×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Cash flows from operating activities
Net loss$(248,509)$(374,384)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization37,84043,180
Stock-based compensation41,71362,217
Asset impairment5,956
Lease expense10,45911,755
Loss on disposal of a business4,502

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s business segments — D&A?
Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — D&A of $18.17M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s business segments — D&A changed year-over-year?
Recursion Pharmaceuticals, Inc.'s business segments — D&A decreased by 30.6% year-over-year, from $26.19M to $18.17M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — D&A?
Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — D&A has grown at a 92.4% compound annual growth rate (CAGR), from $11.76M to $83.7M.
What does business segments — D&A mean?
Reflects the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the specific business segment. It provides insight into the capital intensity of the segment and the ongoing consumption of its asset base.

Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude